- Home
- LITS vs GANX Comparison
LITS vs GANX Comparison
Compare LITS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITS
- GANX
- Stock Information
- Founded
- LITS 2000
- GANX 2017
- Country
- LITS United States
- GANX United States
- Employees
- LITS N/A
- GANX N/A
- Industry
- LITS Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- LITS Health Care
- GANX Health Care
- Exchange
- LITS Nasdaq
- GANX Nasdaq
- Market Cap
- LITS 96.2M
- GANX 79.8M
- IPO Year
- LITS N/A
- GANX 2021
- Fundamental
- Price
- LITS $1.85
- GANX $3.49
- Analyst Decision
- LITS
- GANX Strong Buy
- Analyst Count
- LITS 0
- GANX 6
- Target Price
- LITS N/A
- GANX $8.00
- AVG Volume (30 Days)
- LITS 539.5K
- GANX 1.3M
- Earning Date
- LITS 11-17-2025
- GANX 11-12-2025
- Dividend Yield
- LITS N/A
- GANX N/A
- EPS Growth
- LITS N/A
- GANX N/A
- EPS
- LITS N/A
- GANX N/A
- Revenue
- LITS N/A
- GANX N/A
- Revenue This Year
- LITS N/A
- GANX N/A
- Revenue Next Year
- LITS N/A
- GANX N/A
- P/E Ratio
- LITS N/A
- GANX N/A
- Revenue Growth
- LITS N/A
- GANX N/A
- 52 Week Low
- LITS $1.46
- GANX $1.41
- 52 Week High
- LITS $9.00
- GANX $3.65
- Technical
- Relative Strength Index (RSI)
- LITS N/A
- GANX 74.54
- Support Level
- LITS N/A
- GANX $2.60
- Resistance Level
- LITS N/A
- GANX $3.05
- Average True Range (ATR)
- LITS 0.00
- GANX 0.34
- MACD
- LITS 0.00
- GANX 0.06
- Stochastic Oscillator
- LITS 0.00
- GANX 89.76
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.